CHMP positive opinion for Kalydeco for the treatment of infants with cystic fibrosis ages 1 month and older – Vertex Pharma
Vertex Pharmaceuticals announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of Kalydeco (ivacaftor)… read more.
